{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:21:11Z","timestamp":1788531671731,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and remains a major cause of chronic kidney disease and kidney failure. Conventional monitoring still depends largely on proteinuria, estimated glomerular filtration rate (eGFR), hematuria, blood pressure and biopsy-based pathological classification. These measures are clinically indispensable, but they mainly capture downstream kidney injury and may lag behind the mucosal and systemic immune events that drive active disease. In the targeted-therapy era, this limitation has become more consequential. Targeted-release budesonide, BAFF\/APRIL dual inhibitors, APRIL inhibitors and complement-directed therapies act at different levels of the IgAN immunopathogenic cascade. Galactose-deficient IgA1 (Gd-IgA1) remains central to disease biology, yet its standalone value as a marker of disease activity or prognosis is limited by assay heterogeneity, ethnic and clinical variability, treatment exposure and differences in histopathological context. Increasing evidence suggests that the pathogenicity of IgA depends not only on Gd-IgA1 concentration, but also on mucosal origin, polymeric state, autoantibody binding, immune-complex formation, mesangial retention and complement activation. This Review synthesizes recent advances in immune biomarker monitoring in IgAN, with emphasis on mucosal immune activity, Gd-IgA1, polymeric IgA, IgA-containing immune complexes, complement activation and kidney injury biomarkers. Its contribution is not another undifferentiated catalog of candidate markers. Instead, biomarkers are organized according to their position in the disease cascade and their relationship to treatment mechanism: upstream mucosal immune activation, pathogenic IgA immune-complex burden, complement-mediated intrarenal amplification and tissue injury, and conventional clinical outcomes. The framework is intended to support mechanistic research, trial enrichment and longitudinal pharmacodynamic assessment, while distinguishing established clinical measures from biomarkers that remain investigational. Its use for treatment selection or routine precision monitoring requires prospective validation and assay standardization.<\/jats:p>","DOI":"10.3389\/fmed.2026.1917560","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:41:01Z","timestamp":1788529261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Layered immune biomarker monitoring in IgA nephropathy: from mucosal IgA dysregulation to precision therapeutic response assessment"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuanyue","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tianjin Fifth Central Hospital (Peking University Binhai Hospital)","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tianjin Fifth Central Hospital (Peking University Binhai Hospital)","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanxi Provincial People\u2019s Hospital, The Fifth Clinical Medical College of Shanxi Medical University","place":["Taiyuan, China"]},{"name":"Shanxi Kidney Disease Institute","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy.","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin a nephropathy (IgAN) and immunoglobulin a vasculitis (IgAV).","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/jcm10163467","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don\u2019t know.","volume":"10","author":"Ohyama","year":"2021","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.kint.2025.07.038","article-title":"Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.","volume":"108","author":"Novak","year":"2025","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1209394","DOI":"10.3389\/fimmu.2023.1209394","article-title":"Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s40620-023-01874-8","article-title":"Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.","volume":"37","author":"Vaz de Castro","year":"2024","journal-title":"J Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.","volume":"82","author":"Zhao","year":"2012","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.5858\/arpa.2023-0190-OA","article-title":"Correlation of serum galactose-deficient IgA1 and Oxford class in cases of IgA nephropathy.","volume":"148","author":"Shukla","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.02.034","article-title":"Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouse.","author":"Wu","year":"2026","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part a of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin a nephropathy.","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin a nephropathy: insights from the NEFIGAN trial.","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy.","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa2514415","article-title":"Telitacicept for IgA nephropathy - interim analysis of a phase 3 Trial.","volume":"394","author":"Lv","year":"2026","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy.","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy.","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy.","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group.","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 B cells in the circulation of iga nephropathy patients carry preferentially lambda light chains and mucosal homing receptors.","volume":"33","author":"Zachova","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.kint.2025.12.026","article-title":"Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+\u03b27+ cells in IgA nephropathy.","volume":"109","author":"Liu","year":"2026","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.kint.2021.04.026","article-title":"Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.","volume":"100","author":"Kano","year":"2021","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/ndt\/gfae052","article-title":"IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.","volume":"39","author":"Zhu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.","volume":"97","author":"Makita","year":"2020","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0166700","DOI":"10.1371\/journal.pone.0166700","article-title":"Aberrant IgA1 glycosylation in IgA nephropathy: a systematic review.","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1681\/ASN.2020081208","article-title":"O- and N-Glycosylation of serum immunoglobulin a is associated with IgA nephropathy and glomerular function.","volume":"32","author":"Dotz","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1038\/s41467-025-60819-w","article-title":"Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.","volume":"16","author":"Si","year":"2025","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/ki.2015.158","article-title":"Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.","volume":"88","author":"Berthelot","year":"2015","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"sfaf203","DOI":"10.1093\/ckj\/sfaf203","article-title":"Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1751549","DOI":"10.3389\/fimmu.2026.1751549","article-title":"Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy.","volume":"17","author":"Fu","year":"2026","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.0000000000000290","article-title":"Mesangial C3 deposition, complement-associated variant, and disease progression in IgA nephropathy.","volume":"18","author":"Kang","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1357869","DOI":"10.3389\/fimmu.2024.1357869","article-title":"Urinary complement biomarkers in immune-mediated kidney diseases.","volume":"15","author":"Kesarwani","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy.","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B33","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin a Nephropathy (ARTEMIS-IgAN).","year":"2026"},{"key":"B34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12882-026-04965-3","article-title":"Urinary IL-18 predicts progression of IgA nephropathy.","volume":"27","author":"Tang","year":"2026","journal-title":"BMC Nephrol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10340","DOI":"10.3390\/ijms251910340","article-title":"New insights and future perspectives of APRIL in IgA Nephropathy.","volume":"25","author":"Muto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A Phase 3 Trial of atacicept in patients with IgA nephropathy.","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"B38","unstructured":"Gd-IgA1 Biomarker Screening Now Available. Cincinnati Children\u2019s Hospital Medical Center.\n          \n          2025"},{"key":"B39","unstructured":"Galactose Deficient IgA1 (KM55) Immunostain, Technical Component Only.\n          \n          2026"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan.","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.intimp.2020.107282","article-title":"Immune characteristics of renal allograft donors with mesangial IgA deposition.","volume":"91","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy.","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1917560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:41:02Z","timestamp":1788529262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1917560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":42,"alternative-id":["10.3389\/fmed.2026.1917560"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1917560","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1917560"}}